CPRX Catalyst Pharmaceuticals Inc

Price (delayed)

$5.73

Market cap

$592.28M

P/E Ratio

8.3

Dividend/share

N/A

EPS

$0.69

Enterprise value

$469.07M

Highlights
Catalyst Pharmaceuticals's equity has surged by 79% YoY and by 5% QoQ
Catalyst Pharmaceuticals's quick ratio has surged by 68% YoY and by 60% QoQ
Catalyst Pharmaceuticals's net income has surged by 68% YoY but it has decreased by 3.7% QoQ
The EPS has soared by 64% year-on-year but it has declined by 4.2% since the previous quarter
The stock's P/E is 22% more than its last 4 quarters average of 6.8

Key stats

What are the main financial stats of CPRX
Market
Shares outstanding
103.36M
Market cap
$592.28M
Enterprise value
$469.07M
Valuations
Price to earnings (P/E)
8.3
Price to book (P/B)
3.33
Price to sales (P/S)
4.95
EV/EBIT
11.51
EV/EBITDA
11.26
EV/Sales
3.9
Earnings
Revenue
$120.14M
EBIT
$40.74M
EBITDA
$41.64M
Free cash flow
$40.71M
Per share
EPS
$0.69
Free cash flow per share
$0.39
Book value per share
$1.72
Revenue per share
$1.16
TBVPS
$1.9
Balance sheet
Total assets
$197.22M
Total liabilities
$18.57M
Debt
$4.13M
Equity
$178.65M
Working capital
$147.1M
Liquidity
Debt to equity
0.02
Current ratio
11.19
Quick ratio
10.32
Net debt/EBITDA
-2.96
Margins
EBITDA margin
34.7%
Gross margin
85.4%
Net margin
60.1%
Operating margin
33.6%
Efficiency
Return on assets
41.5%
Return on equity
46.9%
Return on invested capital
121.1%
Return on capital employed
22.3%
Return on sales
33.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CPRX stock price

How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
0%
1 week
-0.17%
1 month
1.78%
1 year
27.62%
YTD
71.56%
QTD
24.3%

Financial performance

How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$120.14M
Gross profit
$102.57M
Operating income
$40.4M
Net income
$72.22M
Gross margin
85.4%
Net margin
60.1%
Catalyst Pharmaceuticals's net income has surged by 68% YoY but it has decreased by 3.7% QoQ
Catalyst Pharmaceuticals's net margin has surged by 66% YoY but it has decreased by 4.6% QoQ
The operating margin fell by 8% YoY and by 3.2% QoQ
The company's operating income fell by 7% YoY and by 2.2% QoQ

Growth

What is Catalyst Pharmaceuticals's growth rate over time

Valuation

What is Catalyst Pharmaceuticals stock price valuation
P/E
8.3
P/B
3.33
P/S
4.95
EV/EBIT
11.51
EV/EBITDA
11.26
EV/Sales
3.9
The EPS has soared by 64% year-on-year but it has declined by 4.2% since the previous quarter
The stock's P/E is 22% more than its last 4 quarters average of 6.8
Catalyst Pharmaceuticals's equity has surged by 79% YoY and by 5% QoQ
The stock's price to book (P/B) is 24% less than its 5-year quarterly average of 4.4 but 23% more than its last 4 quarters average of 2.7
The price to sales (P/S) is 46% higher than the last 4 quarters average of 3.4

Efficiency

How efficient is Catalyst Pharmaceuticals business performance
The ROIC has dropped by 50% year-on-year and by 46% since the previous quarter
The ROE has decreased by 16% from the previous quarter and by 10% YoY
CPRX's return on assets is down by 15% since the previous quarter and by 2.1% year-on-year
The ROS has declined by 11% year-on-year and by 3.7% since the previous quarter

Dividends

What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPRX.

Financial health

How did Catalyst Pharmaceuticals financials performed over time
CPRX's current ratio has soared by 69% year-on-year and by 60% since the previous quarter
Catalyst Pharmaceuticals's quick ratio has surged by 68% YoY and by 60% QoQ
Catalyst Pharmaceuticals's debt is 98% lower than its equity
CPRX's debt to equity has surged by 100% year-on-year
Catalyst Pharmaceuticals's equity has surged by 79% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.